The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 5, 2010, Pages 631-639

  Gridelli, Cesare ^a   Rossi, Antonio ^a   Bareschino, Maria Anna ^a   Schettino, Clorinda ^a   Sacco, Paola Claudia ^a   Maione, Paolo ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Figitumumab; Histology; Insulin like growth factor 1 receptor; NSCLC; Squamous carcinoma

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; A 928605; AMG 479; AVE 1642; BEVACIZUMAB; BIIB 022; BMS 536924; BMS 554417; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CP 751871; DALOTUZUMAB; ERLOTINIB; FIGITUMUMAB; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; GSK 1904529A; IMC A 12; MK 0646; NVP AEW 541; OSI 906; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; ROBATUMUMAB; SCH 717454; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALPHA CHAIN; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BETA CHAIN; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; CORRELATION ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SAFETY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOLOGY; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MYELOMA; NAIL DISEASE; PANCREAS CANCER; PARESTHESIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; REVIEW; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; LUNG NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 77951460650     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003767434     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. A Cancer J Clin 2005;55:74-108
3. NSCLC Meta-Analyses Collaborative roup. Chemotherapy in addition to upportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):iv68-70
5. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006;355:2542-2550
7. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010. [Epub ahead of print]
8. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191
9. Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors in lung cancer. Oncology 2009;77(suppl.1):90-96
10. Clemmons DR, Modifying IG. F1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007;6:821-833
11. Denley A, Cosgrove LJ, Booker GW, et al. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005;16:421-439
12. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008;19:111-120
13. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137
14. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-39695
15. Brown J, Delaine C, Zaccheo OJ, et al. Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 2008;27:265-276
16. Oh SH, Lee OH, Schroeder CP, et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006; 5:2685-2695
17. Myers MG Jr, Grammer TC, Wang LM, et al. Insulin receptor substrate-1 mediates phosphatidylinositol 39-kinase and p70S6K signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 1994;269:28783-28789
18. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-468
19. Zhang X, Kamaraju S, Hakuno F, et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004;83:161-170
20. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34
21. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-163
22. Baserga R, Hongo A, Rubini M, et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997;1332:F105-26
23. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase akt. Science 1997;275:661-665
24. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997;11:701-713
25. Khwaja A, Rodriguez-Viciana P, Wennstrom S, et al. Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997;16:2783-2793
26. Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-1606
27. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004;29:233-242
28. Peruzzi F, Prisco M, Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-7215
29. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3¢-kinase and mitogen-activated protein kinase pathways. J Biol Chem 1997;272:154-161 (Pubitemid 27021138)
30. Pronk GJ, McGlade J, Pellicci G, et al. Insulin-induced phosphorylation of the 46-and 52-kDa Shc proteins. J Biol Chem 1993;268:5748-5753
31. Sasaoka T, Draznin B, Leitner WJ, et al. Shc is the predominant signaling molecule coupling insulin receptors to activation of guanine nucleotide releasing factor and p21ras-GTP formation. J Biol Chem 1994;269:10734-10738
32. Sasaoka T, Rose DW, Jhun BH, et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 1994;269:13689-13694
33. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-156
34. London SJ, Yuan JM, Travlos GS, et al. Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002;94:749-754
35. Chang YS, Wang L, Liu D, et al. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002;8:3669-3675 (Pubitemid 35424756)
36. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503-2512
37. Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001;8:1058-1063
38. Garber K. IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst 2005;97:790-792
39. Karp DD, Pollak MN, Cohen RB, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 2009;4:1397-1403
40. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009;27:2516-2522
41. Merrick DT, Dziadziuszko R, Szostakiewicz B, et al. High insulin-like growth factor 1 receptor (IGF1R) expression is associated with poor survival in surgically treated non-small cell lung cancer (NSCLC) patients (pts) [abstract 7550]. J Clin Oncol 2007;25(18S):397s
42. Available from: http://www.pfizer.com/news/press-releases/pfizer-press- releases. jsp (accessed on January 6, 2010)
43. Available from: http://www.cancer.gov/(accessed on February 26, 2010)
44. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-207
45. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:11637
46. van der Veeken J, Oliveira S, Schiffelers RM, et al. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9:748-760
47. Cappuzzo F, Toschi L, Tallini G, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120-1127
48. Ludovini V, Bellezza G, Pistola L, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 2009; 20:842-849
49. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009;4:e7273
50. Rowinski EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549s-55s
51. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807
52. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract 3519]. J Clin Oncol 2008;26(15S):157s
53. Hidalgo M, Tirado Gomez M, Lewis N, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule [abstract 3520]. J Clin Oncol 2008;26(15S):158s
54. Moreau P, Hulin C, Facon T, et al. Phase I study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood 2007;110:1166
55. Tolcher AW, Patnaik A, Till E, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor 1 receptor) antagonist, in patients (pts) with advanced solid tumor (ST) [abstract 3582]. J Clin Oncol 2008;26(15S):173s
56. Wang Y, Lipari P, Wang X, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther 2010;9:410-418
57. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008;3:815-818